Abstract: OBJECTIVE To investigate clinical efficacy evaluation and potential mechanism of Shenfukang capsule (SKC) in treatment to chronic glomerulonephritis (CGN) based on integration meta analysis and network pharmacology research strategy. METHODS The Chinese and English literature of the randomized controlled trials (RCTs) about SKC in treatment on CGN were comprehensively searched.The quantitative literature was determined based on the criteria of inclusion and exclusion.The meta analysis of the included data was carried out by the Review Manager.The chemical components and the target of action,disease targets,common targets,and other related information of SKC were screened based on network pharmacology.The key pathway was annotated,and the potential mechanism of SKC intervention in CGN was explored based on bioinformatics technology.RESULTS A total of 11 RCTs were included,which were involving 938 patients.Meta analysis showed that the effective rate,lymphocyte subsets (CD4,CD4/CD8 increased and CD8 decreased),fibrinolytic system,and renal function indexes in the therapy group were superior to those in the control group (P<0.05).A total of 27 chemical components and 97 potential targets extremely closely related to CGN were obtained through the online database,which was related to AGE/RAGE pathway,lipid and atherosclerosis,TNF signaling pathway,IL-17 signaling pathway,and other molecular processes.CONCLUSION SKC intervention in CGN is an integration effect of multi-component,multi-target,multi-links integration effect,mainly through the regulation of autoimmunity,oxidative stress,inflammatory response,and other ways to achieve therapeutic purposes.